Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices

Access Activity

Overview / Abstract:

Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status should be determined for all patients. To optimize treatment, clinicians must not only have current knowledge of current biomarker testing and treatment selection, but also the operational frameworks to effectively translate this latest evidence into practice. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensure your patients are benefitting from the latest advancements in care.

Expiration

Jun 28, 2025

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online, Webinar / Webcast / Video

Credits / Hours

1.0

Accreditation

ACCME, MIPS QPP

Presenters / Authors / Faculty

Manish A. Shah, MD, FASCO
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY

Geoffrey Ku, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Sponsors / Supporters / Grant Providers

Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

Supported by educational grants from Merck & Co., Inc. and Astellas Pharmaceuticals.

Keywords / Search Terms

ACHL CME, CE, ACCME, MIPS, University of Chicago, Merck, Astellas, Ku, Shah, gastric, gastroesophageal, cancer, GAS/GEJ, HER2, PD-L1, biomarker testing, gastroenterology, oncology, pathology, sequencing, multidisciplinary, adverse, novel, second-line therapy, treatment plan, microsatellite instability Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map